Screening for Human Papillomavirus in a Low- and Middle-Income Country

Aaron E. Atkinson, PhD1,2; Carlos Alberto Matute Mandujano, MD3; Suyapa Bejarano, MD4; Linda S. Kennedy, MEd1,2; and Gregory J. Tsongalis, PhD1,2

PURPOSE Low- and middle-income countries have high incidences of cervical cancer linked to human papillomavirus (HPV), and without resources for cancer screenings these countries bear 85% of all cervical cancer cases. To address some of these needs, brigade-style screening combined with sensitive polymerase chain reaction–based HPV testing to detect common high-risk HPV genotypes may be necessary.

METHODS We deployed an inexpensive DNA extraction technique and a real-time polymerase chain reaction–based HPV genotyping assay, as well as Papanicolaou testing, in a factory in San Pedro Sula, Honduras, where 1,732 women were screened for cervical cancer.

RESULTS We found that 28% of participants were positive for high-risk HPV, with 26% of HPV-positive participants having more than one HPV infection. Moreover, the most common HPV genotypes detected were different than those routinely found in the United States.

CONCLUSION This work demonstrates a deployable protocol for HPV screening in low- and middle-income countries with limited resources to perform cytopathology assessment of Pap smears.

INTRODUCTION Cervical cancer in low- and middle-income countries (LMICs) accounts for 85% of an estimated 528,000 new cases globally and 266,000 deaths annually.1-3 In many LMICs, cervical cancer is the leading cause of cancer-related mortality and attributable to limited screening programs. A lack of funding, trained cytopathologists to review Papanicolaou test slides, and other health care providers for follow-up care that comprise the needed infrastructure does not allow for routine cervical cancer screening. To alleviate some of these burdens associated with cervical cancer screening, we developed and validated a process with which to screen women using a simple, high-risk human papillomavirus (hrHPV) DNA test.4 We demonstrate that DNA testing for hrHPV using crude cell lysates and real-time polymerase chain reaction (PCR) with lyophilized reagents was feasible to perform in a mobile system so that women in various regions of Honduras could be tested.5

As the causative agent for cervical cancer, detection of hrHPV types, which is less subjective, has the potential to improve outcomes relative to less-sensitive visual or cytologic tests.6-11 Several low-cost HPV screening tests have been developed specifically for use in LMICs. Two of these tests, however, cannot distinguish between HPV types or resolve coinfections known to have higher rates of cervical disease, whereas a third less-sensitive immunologic test only detects HPV types 16, 18, and 45.12-15 Cervical cancer screening guidelines have recently been published that recommend DNA testing for the detection of hrHPV in a liquid cytology sample as a sole test or in conjunction with Papanicolaou test.16 Use of instrumentation and assays that are US Food and Drug Administration approved in the United States is not feasible, nor sustainable, in Honduras as a result of cost and facility logistics. We therefore developed a low-cost, simple DNA testing method for hrHPV using a crude cell lysate and real-time PCR instrument.4,5 In several studies, we showed that hrHPV type distributions were more reflective of those found in Asia than in North America.4,5,17 This geographically unexpected distribution underscores the need for HPV genotype surveillance to effectively triage hrHPV-positive participants for follow-up care and to strategize the implementation of successful vaccination programs.18

In the current study, we determine the hrHPV type frequency in women working in a manufacturing facility in San Pedro Sula, Honduras.
METHODS

This study was approved by the Dartmouth Committee for the Protection of Human Subjects and the Universidad de Catolica in San Pedro Sula, Honduras. Cervical samples were collected using cervical brushes on 1,732 participants who were employees at a manufacturing site in San Pedro Sula, Honduras, for Papanicolaou test and hrHPV testing. Samples were collected by trained physicians and medical students. Participants with a positive hrHPV result underwent a follow-up examination at a local cancer center.

All cervical brushes and corresponding Papanicolaou test slides were assigned a unique study identification number (Fig 1A). After slide prep, brushes were misted with ethanol and air dried before being individually packaged and stored at room temperature for 30 to 40 days before processing. Cell lysates from cervical swabs were made as previously described with several modifications.4 In brief, dried cervical brushes were cut and placed inside individual tubes that contained 400 µL of cell lysis buffer consisting of 50 mM NaOH and 0.2 mM EDTA in nuclease-free water (Fig 1B). Tubes were boiled for 10 minutes using an inexpensive locally sourced rice cooker, the plastic colander of which had been bored out to accommodate the 1.5-mL screw-cap tubes (Fig 1C). Next, 17 µL of 70 mM Tris pH 8.0 was added to rehydrate the assay tubes that contained lyophilized MeltPro high-risk genotyping reagents (QuanDx/Zeesan Biotech, San Jose, CA). Finally, 8 µL of cell lysate was added to the rehydrated reaction tubes for a final volume of 25 µL. Separately, 25 µL of each positive and negative control or 17 µL of a neutralization solution was added to the two remaining reaction tubes (Fig 1D).

Real-time polymerase chain reaction (RT-PCR) and multicolor melt-curve analysis were performed (Fig 1F). A report was compiled from the results provided by the instrument software. HPV, human papillomavirus; n, patient accession number.

FIG 1. Flowchart of rice cooker boiling alkaline lysis DNA extraction. (A) Cervical brushes were obtained and accessioned. (B) Brushes were cut to fit a tube that contained 400 µL lysis buffer. (C) Tubes were placed in the colander of a rice cooker and boiled for 10 minutes. (D) Twenty-five microliters of the supplied and resuspended positive and negative controls were added to two reaction tubes and 17 µL of 70 mM Tris pH 8.0 was added to the remaining reaction tubes. (E) Eight microliters of each sample was added to reaction tubes for a final volume of 25 µL. (F) Real-time polymerase chain reaction (RT-PCR) and multicolor melt-curve analysis were performed. (G) A report was compiled from the results provided by the instrument software. HPV, human papillomavirus; n, patient accession number.
negative control were pipetted into lyophilized reagent tubes (Figs 1D and 1E). Rehydrated reagents with cell lysate were then mixed and loaded directly onto the SLAN-96 real-time PCR instrument (QuanDx/Zeesan Biotech) and run using the SLAN 8.2.2 software per the manufacturer’s protocol. HPV typing results were available within 2.5 hours (Figs 1F and 1G).

This assay can detect and distinguish 14 high-risk HPV types (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in addition to an internal human DNA sequence control. This is accomplished through a multiplexed PCR with end point melt-curve analysis that resolves type-specific melting temperatures for four distinct probes labeled with ROX (HPV 31, 33, 16, 35, 68, and 18), CY5 (HPV 56, 52, 45, and 39), FAM (HPV 59, 66, 58, and 51), and HEX for the internal control (Table 1). Sample results using the system were negative, HPV positive by type, or invalid as a result of a failed reaction that did not generate either signal for the internal control or HPV. Invalid samples were collected and stored until repeat reactions could be performed after the addition of 20 µL of 1 M Tris pH 8.0. Each kit is supplied with both lyophilized reagents and controls which did not require refrigeration during the course of these experiments.

**RESULTS**

Of 1,732 samples, 480 (28%) were positive for high-risk HPV, and 1,199 samples (69%) had no detectable HPV. Fifty-three samples (3%) failed to amplify either the internal control or an HPV target and were deemed to be invalid and subsequently unable to type (Fig 2A). HPVs 58, 35, and 16 were the most common genotypes present with 90 (19% of positive samples), 64 (13% of positive samples), and 63 (13% of positive samples) infections, respectively (Fig 2B). Of note, there were only 31 HPV 18-positive samples.

Among 480 HPV-positive samples, 126 (26%) were positive for two or more HPV genotypes. There were five participants with HPV 58/HPV 16 coinfections and a single participant with an HPV 58/HPV 35 coinfection. No HPV 16/HPV 35 or HPV 16/HPV 18 coinfections were identified.

**DISCUSSION**

Cervical cancer screening strategies, including cytologic and HPV screens designed for higher-income countries with widespread health care access and reliable follow-up care, are difficult to implement in LMICs where those resources are scarce. Cytologic examination in LMICs is costly and the number of cytologists available is not sufficient to perform the analyses, especially in countries in which gaps in health care access are prevalent. Resolving these problems requires a paradigm shift. Low-cost HPV screening techniques offer a potential solution as there is

| Channel | Genotype | Tm, °C |
|---------|----------|--------|
| ROX     | HPV-31   | 49 ≤ Tm < 53 |
|         | HPV-33   | 53 ≤ Tm < 59 |
|         | HPV-16   | 59 ≤ Tm < 64 |
|         | HPV-35   | 64 ≤ Tm < 68 |
|         | HPV-68   | 68 ≤ Tm < 73 |
|         | HPV-18   | 73 ≤ Tm < 77 |
| CY5     | HPV-56   | 45 ≤ Tm < 52 |
|         | HPV-52   | 52 ≤ Tm < 57 |
|         | HPV-45   | 57 ≤ Tm < 63 |
|         | HPV-39   | 63 ≤ Tm < 70 |
| FAM     | HPV-59   | 44 ≤ Tm < 48 |
|         | HPV-66   | 48 ≤ Tm < 54 |
|         | HPV-58   | 54 ≤ Tm < 60 |
|         | HPV-51   | 60 ≤ Tm < 74 |
| HEX     | Internal control | 50 ≤ Tm < 70 |

NOTE. Genotypes are organized by the fluorescent channel in which they are read.

Abbreviation: Tm, temperature.
now strong evidence to show that HPV-based screening assays are not only a more sensitive means with which to detect underlying cervical abnormalities compared with conventional cytology, but can also be performed by nontechnical staff. Moreover, higher negative predictive values with PCR-based HPV tests offer longer reassurance to patients that they are not at substantial risk of developing cervical cancer. In this context, DNA-based HPV screening methods are less subjective, more robust, and have been shown to have higher sensitivity and the ability to distinguish between many coinfections that increase the risk of cervical disease.
For the 480 participants (28%) we identified with HPV infection, the benefits of screening will, we hope, translate into earlier interventions and a reduction in overall cervical cancer rates upon referral for cytologic examination and follow-up. For the remaining 1,202 HPV-negative participants (69%), there is strong confidence that they are relatively safe from developing cervical cancer for the next 5 years. However, continued and diligent HPV screening is critical for sustained impact and effectiveness of cervical cancer prevention. High-risk HPV screening should include data on vaccinations and genotypic information for both infection prevalence and HPV-related cancers. Such screening programs already have documented suppression of HPVs 16 and 18 in response to the bivalent vaccine. In other studies, particularly those in areas with prevaccine HPV genotype distributions that are known to include genotypes not included in vaccines, such as HPV 58, controversial active surveillance is underway to closely monitor for the potential of type replacement after widespread use of the bivalent vaccine.

In the current study, we found no HPV 16 and HPV 18 coinfections and relatively few single HPV 16 or HPV 18 infections; therefore, direct coverage provided by the bivalent vaccine against infection and possible progression to cervical cancer would equate to approximately 14% among those that are HPV positive in this study. When considering the nonavalent vaccine that covers HPVs 6, 11, 16, 18, 31, 33, 45, 52, and 58, approximately 47% of those that are HPV positive in this study could receive some amount of protection from either single or coinfections and possible progression to cervical cancer among those genotypes. However, approximately 53% of participants in the current study would not have benefited from the nonavalent vaccine on the basis of genotype prevalence alone (Fig 2B). There may be some cross-reactive protection against HPV 31 and potentially HPVs 33 and 45, although data on any bivalent vaccine is limited.

**FIG 4.** Instrument thermal profiles. (A) Reaction proceeding without power interruption and (B) with various interruptions to instrument power. Thermal cycler lid temperature (red); block temperature (blue).
vaccine cross-protection are mixed.\textsuperscript{17,27,30} In this study of factory workers in San Pedro Sula, Honduras, our results show a prevalence of HPV 58 and HPV 35 infections, with 90 (19%) and 64 (13%) of 480 infections, respectively (Fig 2B). Neither of these genotypes would be covered by the Honduran bivalent vaccination program. In addition, with 26% of HPV-positive participants having more than one detectable HPV genotype, our data underscore the benefit of HPV screening that is able to differentiate coinfection hrHPV types for epidemiologic purposes, as these participants are at the greatest risk for cervical cancer.\textsuperscript{15,31}

Global HPV genotype distribution is broadly known to have geographic differences that must be considered for cervical cancer prevention and surveillance strategies. Our previous work found a high prevalence of HPV 52 in an isolated Honduran community located in the largest wilderness tract in Central America.\textsuperscript{6} HPV 52 was also found in neoplastic lesions at a prevalence that was higher than expected in Mexico.\textsuperscript{32} Similarly, HPV 52 and 58 are known to have a higher distribution in Asia relative to other regions.\textsuperscript{28,33} Not surprisingly, subsequent studies found that HPV 58 accounts for a larger proportion of cervical cancer burden in Asia than elsewhere.\textsuperscript{34,35}

The HPV distribution identified in this participant population and limited number of in-country pathologists makes the use of primary HPV testing, as described here, both critical and effective, especially given the interim clinical guidance for the use of such testing for cervical cancer screening.\textsuperscript{31} Triaging patients on the basis of positive HPV status within these guidelines not only allows for the most effective use of the limited number of pathologists, but the HPV genotypic information provides critical information for both patient care and to support vaccination strategies adopted in those countries.\textsuperscript{27} A limitation of the current study is in the convenience sampling with respect to women working in a single factory in one Honduran city as well as the age of participants being limited to a working group.

Last, the low-cost DNA lysate and sensitive HPV assay described here allowed us to process 94 samples in less than 2.5 hours and return rapid genotype-specific results. This approach offers the following benefits: in contrast to other PCR-based assays that use hydrolysis probes, the equipment can be run off of a generator or variable power sources, as the system returns results despite power interruptions (Fig 4); the PCR system itself uses LEDs that require little, if any, maintenance; the DNA extraction method uses minimal and readily available disposables; lyophilized reagents were tested without refrigeration for 2 weeks and maintained their efficacy; and the combination of lyophilized reagents, crude lysate, and HPV genotyping performed by the instrument makes for an easy-to-perform operation that is suitable for testing in locations without highly trained personnel. These features allow for near-patient care diagnosis that is of critical importance for combining screening and treatment strategies in LMICs.

**AFFILIATIONS**

1. Dartmouth Hitchcock Health System, Lebanon, NH
2. Geisel School of Medicine at Dartmouth, Hanover, NH
3. Universidad Católica Honduras, San Pedro Sula, Honduras
4. Liga Contra el Cáncer, San Pedro Sula, Honduras

**CORRESPONDING AUTHOR**

Gregory J. Tsongalis, PhD, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Health System, 1 Medical Center Dr, Lebanon, NH 03756; e-mail: gregory.j.tsongalis@hitchcock.org.

**SUPPORT**

Funded by a generous grant from the Munck-Pfefferkorn Award Committee and the Norris Cotton Cancer Center of the Geisel School of Medicine at Dartmouth, and supported by the Pathology Shared Resource in the laboratory for Clinical Genomics and Advanced Technology at Dartmouth Medical Center.

**AUTHOR CONTRIBUTIONS**

Conception and design: Carlos Alberto Matute Mandujano, Linda S. Kennedy, Gregory J. Tsongalis

Administrative support: Suyapa Bejarano, Linda S. Kennedy

Provision of study materials or patients: Carlos Alberto Matute Mandujano, Suyapa Bejarano

Collection and assembly of data: Aaron E. Atkinson, Carlos Alberto Matute Mandujano, Suyapa Bejarano

Data analysis and interpretation: Aaron E. Atkinson, Carlos Alberto Matute Mandujano, Suyapa Bejarano, Gregory J. Tsongalis

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated.

Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wcc or ascopubs.org/jco/site/ifc.

Suyapa Bejarano
Research Funding: MSD Oncology, Kinex
Travel, Accommodations, Expenses: Pfizer, Asofarma

Gregory J. Tsongalis
Stock and Other Ownership Interests: Chromacode
Honoraria: Chromacode, Seracare, AccuGenomics
Consulting or Advisory Role: AstraZeneca, Seracare
Research Funding: Illumina, QuanDx, Pillar Biosciences, Biocartis

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

The authors thank the employees and management of Gildan in Honduras for their participation and La Liga Contra el Cáncer’s PESCA team of medical students for help in screening participants.
REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
2. Bruní L, Barrionuevo-Rosas L, Albero G, Serrano B, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre) 2017. Report No.: Human Papillomavirus and Related Diseases in Honduras. 2017
3. Cutts FT, Franceschi S, Goldie S, et al: Human papillomavirus and HPV vaccines: A review. Bull World Health Organ 85:719-726, 2007
4. Turner SA, Deharvengt SJ, Lyons KD, et al: Implementation of multicolor melt curve analysis for high-risk human papillomavirus detection in low- and middle-income countries: A pilot study for expanded cervical screening in Honduras. J Glob Oncol 10.1002/1758-2557.e00103, 2018
5. Atkinson A, Studwell C, Bejarano S, et al: Rural distribution of human papilloma virus in low- and middle-income countries. J Exp Mol Path 104:146-150, 2018
6. Denny L, de Sanjosé S, Mutbei M, et al: Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet 389:861-870, 2017
7. Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588, 2007
8. Shi JF, Chen JF, Carfell K, et al.: Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: A micro-costing study. BMC Health Serv Res 12:2012
9. Gradassi A, Burd RD: Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Rev Mol Diagn 17:379-391, 2017
10. Tsakogiannis D, Gartzonika C, Levidiotou-Stefanou S, et al: Molecular approaches for HPV genotyping and HPV-DNA physical status. Expert Rev Mol Med 19:e1, 2017
11. Chrysostomou AC, Stilianou DC, Constantinidou A, et al: Cervical cancer screening programs in Europe: The transition towards HPV vaccination and population-based HPV testing. Viruses 10:E279, 2018
12. Zhao FH, Jeronimo J, Qiao YL, et al: An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) 6:938-948, 2013
13. Ying H, Jing F, Fanghui Z, et al: High-risk HPV nucleic acid detection kit—the careHPV test—a new detection method for screening. Sci Rep 4:4704, 2014
14. Fokom Domgue J, Schiffman M, Wentzensen NH, et al: Assessment of a new lower-cost real-time PCR assay for detection of high-risk human papillomavirus: Useful for cervical screening in limited-resource settings? J Clin Microbiol 55:2348-2385, 2017
15. Chaturvedi AK, Kati HA, Hildesheim A, et al: Human papillomavirus infection with multiple types: Pattern of coinfection and risk of cervical disease. J Infect Dis 203:910-920, 2011
16. US Preventive Services Task Force, Curry SJ, Krist AH, et al: Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 320:674-686, 2018
17. Chan PK: Human papillomavirus type 58: The unique role in cervical cancers in East Asia. Cell Biosci 2:17, 2012
18. Bruní L, Diaz M, Barrionuevo-Rosas L, et al: Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Health 4:e453-e463, 2016
19. Naucler P, Ryd W, Törnberg S, et al: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589-1597, 2007 [Erratum: N Engl J Med 359:1637, 2008]
20. Ronco G, Dillner J, Elfström KM, et al: Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet 383:524-532, 2014
21. Sankaranarayanan R, Nene BM, Shastri SS, et al: HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394, 2009
22. Brotherton JM, Kaldor JM, Garland SM: Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: Towards a national HPV surveillance strategy. Sex Health 7:310-319, 2010
23. Bosch FX, Broker TR, Forman D, et al: Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31:F1-F31, 2013 (suppl 5)
24. Castle PE, de Sanjosé S, Qiao YL, et al: Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 30:F177-F182, 2012 (suppl 5)
25. Kavanagh K, Pollock KG, Cuschieri K, et al: Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: A 7-year cross-sectional study. Lancet Infect Dis 17:1293-1302, 2017
26. Fischer S, Bettstetter M, Becher A, et al: Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination. Oncol Lett 12:601-610, 2016
27. Lee LY, Garland SM: Human papillomavirus vaccination: The population impact. F1000 Res 6:866, 2017
28. Meshri D, Soltan K, Lehtinen M, et al: Population-level effects of human papillomavirus population-based HPV-DNA infections on nonvaccine genotypes. Emerg Infect Dis 22:1732-1740, 2016
29. Malagón T, Drolet M, Boily MC, et al: Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis 12:781-789, 2012
30. Guan P, Howell-Jones R, Li N, et al: Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 131:2349-2359, 2012
31. Huh WK, Ault KA, Chelmow D, et al: Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. J Low Genit Tract Dis 19:91-96, 2015
32. Jaisamrarn U, Castellsagué X, Garland SM, et al: Natural history of progression of HPV infection to cervical lesion or clearance: Analysis of the control arm of the large, randomised PATRiCIA study. PLoS One 8:e79260, 2013 [Erratum: PLoS One 10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a, 2018]
33. Romero-Morelos P, Uribe-Jiménez A, Bandala C, et al: Genotyping of the human papilloma virus in a group of Mexican women treated in a highly specialist hospital: Multiple infections and their potential transcendence in the current vaccination programme (in Spanish). Med Clin (Barc) 149:287-292, 2017
34. Chan PK, Ho WC, Chan MC, et al: Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS One 9:e107573, 2014
35. Clifford GM, Smith JS, Plummer M, et al: Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88:63-73, 2003